Similarities in the Biodistribution of Iodine-Labeled Anti-Tac Single-Chain Disulfide-Stabilized Fv Fragment and Anti-Tac Disulfide-Stabilized Fv Fragment
Nuclear Medicine and Biology, ISSN: 0969-8051, Vol: 25, Issue: 4, Page: 387-393
1998
- 13Citations
- 5Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes13
- 13
- CrossRef10
- Captures5
- Readers5
Article Description
We evaluated the biodistribution and pharmacokinetics of two different iodine-labeled Fv fragments of anti-Tac monoclonal antibody (MAb) in normal and tumor-bearing nude mice. One was a disulfide-stabilized Fv fragment (dsFv), and the other was a single-chain disulfide-stabilized Fv fragment (scdsFv). The scdsFv is a newly developed type of Fv fragment superior to the dsFv in which the V H and V L are linked by covalent bonds through a spacer arm and by an internal disulfide bond. These modifications increase the yield of scdsFv. Both reagents recognize the alpha subunit of the interleukin-2 receptor (IL-2Rα). The biodistribution of the Fv fragments was evaluated in normal mice co-injected with 50 mg of l -lysine and in a no-lysine control group. Biodistribution was also evaluated in nude mice bearing subcutaneous tumor xenografts derived from IL-2Rα-positive ATAC4 cells and receptor-negative A431 cells. These mice were co-injected with 125 I-labeled anti-Tac scdsFv (6 μCi/0.7 μg) and 131 I-labeled anti-Tac dsFv (2 μCi/0.7 μg) or with 131 I-labeled anti-Tac scdsFv (6 μCi/0.7 μg) and 125 I-labeled anti-Tac dsFv (4 μCi/0.7 μg). The biodistribution of 125 I-labeled anti-Tac scdsFv and 131 I-labeled anti-Tac dsFv was very similar in all organs and the tumors. The renal uptake of both reagents was blocked effectively (<93%) and similarly by lysine. The scdsFv cleared slightly faster from the circulation than did the dsFv because there were more aggregates of dsFv than of scdsFv (3% vs. 1%, respectively). The scdsFv-to-dsFv ratio ranged from 0.79 to 1.20 in all organs at all time points we examined. In conclusion, the first biodistribution study of an scdsFv molecule shows that the scdsFv had a biodistribution very similar to that of the dsFv and seems to be a good alternative to the dsFv because of its higher production yield.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S096980519700228X; http://dx.doi.org/10.1016/s0969-8051(97)00228-x; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0031961152&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/9639301; https://linkinghub.elsevier.com/retrieve/pii/S096980519700228X; http://linkinghub.elsevier.com/retrieve/pii/S096980519700228X; http://api.elsevier.com/content/article/PII:S096980519700228X?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S096980519700228X?httpAccept=text/plain; http://dx.doi.org/10.1016/s0969-8051%2897%2900228-x; https://dx.doi.org/10.1016/s0969-8051%2897%2900228-x
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know